Being overweight, hyperlipidemia, hypertension, type II diabetes
mellitus(DM) or high blood sugar, and glucose intolerances are all clinical disorders
collectively referred to as the metabolic syndrome (MetS). MetS affects multiple
systems in the body, including cardiovascular, endocrine, urinary, nervous, and
gastrointestinal systems. Atherosclerosis risk is increased by chronic inflammation and
vascular endothelial dysfunction, which are both closely related to MetS. The risk of
cardiovascular illnesses, the world's leading cause of mortality, is also increased by
metabolic syndrome. Cancers such as the endometrium, breast, colon, liver,
gallbladder, oesophageal, pancreas, kidney, and prostate, also chronic kidney disease,
IBD (idiopathic inflammatory bowel disease), chronic gastritis, and dysplasia, are all
caused by MetS enhanced by abdominal obesity, dyslipidemia, and poor glucose
control. Besides, those with normal glucose metabolism are more likely to develop
various peripheral nerve issues related to MetS. There is a connection between MetS
and a number of cognitive deficiencies. Endocrine-disrupting substances (EDS) also
have a detrimental effect on human health, which includes their influence on metabolic
procedures. The gold standard for non-invasive pancreatic fat quantification is
magnetic resonance spectroscopy (MRS). Anthropometry is quickly and accurately
assessed on a wide scale by three-dimensional (3D) body surface scanners (BS).
Indicators of waist circumference, sagittal diameter, and body weight are strongly
correlated with areas of deep abdominal adipose tissue in both sexes. Each system
listed above is examined in this chapter in relation to MetS, new diagnostic insights are
presented, and pathogenesis and consequences that were not identified and treated as
early on are summarized.
Keywords: Abdominal obesity, BMI, Metabolic syndrome, Neuropathy.
